Findings from a new study suggest that long-term testosterone therapy (TTh) may reduce the risk of cardiovascular (CV) death.
In the multicentre observational, prospective, registry study of 656 men with total testosterone of 12.1nmol/L or less and symptoms of hypogonadism, 360 received parenteral testosterone undecanoate (TU) for up to 10 years.
The findings, published in the Journal of Cardiovascular Pharmacology and Therapeutics , report that there were two deaths in the TTh group and neither was related to CV events. In the non-treated control group, there were 21 deaths, 19 of which were related to CV events. There were 26 non-fatal myocardial infarctions and 30 non-fatal strokes in the control group, but none in the T-treated group.
“The low CV events observed in the testosterone group compared to the untreated group strongly suggest that TTh is protective. We believe that the protective effect of testosterone on the CV system provides clinicians with the opportunity to utilise this approach for secondary prevention for hypogonadal men with a history of CV events,” explained co-author Abdulmaged M. Traish.